[
    {
        "question":"what is the scope of passing this further to our customers and hence what would be the sustainable gross margin as far as generic API business is concerned?",
        "answer":"The scope of passing the decrease in raw material prices to customers in the generic API business may be limited, especially for products under long-term arrangements where maintaining margins is more feasible. This could potentially lead to a sustainable gross margin for the company in the generic API business.",
        "contexts":[
            "M. Satish Choudhury: Thank you, ma\u2019am. With this, we would request the moderator to open the line for Q&A.\n\nModerator: Thank you very much. Ladies and gentlemen, we will now begin the question and answer session. The first question is from the line of Tushar Manudhane from Motilal Oswal. Please go ahead.\n\nTushar Manudhane: I was referring to your comment with respect to the raw material prices moving down, so just would like to understand what is the scope of passing this further to our customers and hence what would be the sustainable gross margin as far as generic API business is concerned?\n\nPage 5 of 17\n---\n# Divi\u2019s Laboratories Limited\n\nAugust 14, 2023",
            "Page 14 of 17\n---\n# Divi\u2019s Laboratories Limited\n\nAugust 14, 2023\n\nenvironment friendly that will allow us to be the leader, but they will add up 2, 3, 4, 5 each year and we expect a much bigger basket than what we are in now. We are not talking about new products, new generics, we are talking about the generic products where we are already in, where we have a presence and we see that they will grow. People are living longer. As I said we are more into lifestyle medicines than lifesaving medicine\u2026. our generic products, so as people live longer they have to use longtime the lifestyle medicines.\n\nCyndrella Carvalho: And sir, if I may understand that from a 3-4 year perspective, what should be our goal from a topline and the margin perspective, you mentioned 35% to 40% is the larger range, but again the earlier call also, you have mentioned the double digit, should we affirm these two numbers again?",
            "Moderator: Thank you. The next question is from the line of Cyndrella Carvalho from JM Financial. Please go ahead.\n\nCyndrella Carvalho: Congratulations on the guided gross margin improvement, we are seeing this improvement coming and Nilima highlighted that this is driven by lower raw material cost as well as the further improvement in the other expenses that we are seeing is largely the logistical cost also coming down. So, how should we see this, the gross margin. A) is: do we see some improvement in our generic pricing portfolio also or it is purely by the raw material and the B) part is: on the other expenses side, should we see further scope of improvement as we go ahead?",
            "Page 5 of 17\n---\n# Divi\u2019s Laboratories Limited\n\nAugust 14, 2023\n\nDr. Murali K. Divi: In the generic portfolio, based on the competition, if the general prices of raw materials have come down, probably the demand from the generic industry may be there asking us to bring down the prices, but where we are in generic industry lump products where with long term arrangements, usually we don't have that. So we will be able to retain the extra margin whereas in custom synthesis, we can retain the margin when the raw materials goes down or raw materials go up to a certain percentage beyond which we will discuss.\n\nModerator: Thank you. The next question is from the line of Cyndrella Carvalho from JM Financial. Please go ahead."
        ],
        "ground_truth":"In the generic portfolio, based on the competition, if the general prices of raw materials have come down, probably the demand from the generic industry may be there asking us to bring down the prices, but where we are in generic industry lump products where with long term arrangements, usually we don't have that. So we will be able to retain the extra margin whereas in custom synthesis, we can retain the margin when the raw materials goes down or raw materials go up to a certain percentage beyond which we will discuss.",
        "file_name":"Divi's Laboratories.pdf"
    },
    {
        "question":"Just on the split of generic and custom that was shared, so when I just add the generic piece and the nutraceuticals together and look at growth on Y-o-Y basis, it seems to be still subdued, like low single digit, like flattish kind of a Y-o-Y trend, even if I look at it compared to the quarter before also, it seems to have declined. So, just want to understand and also reflect upon our guidance for fiscal 24 when we exclude Molnupiravir we are looking at double digit growth, so if you can help us understand that, sir?",
        "answer":"The growth of matured generics is indeed in the single digits, but even a single digit growth can be substantial when considering the overall quantity of generic API. In a compound of 5000 tons, a 5% growth would translate to a 250 ton increase year-on-year. It is important to note that there may be new entrants in the market taking up some capacity or products, especially in highly regulated advanced markets. As the market stabilizes post-COVID, focusing on lifestyle medicines in the generic market, there should be an improvement in growth. The company aims for steady and consistent growth, targeting double digits, provided there are no major unforeseen incidents like COVID or issues in specific countries.",
        "contexts":[
            "Moderator: Thank you. The next question is from the line of Shyam Srinivasan from Goldman Sachs. Please go ahead.\n\nShyam Srinivasan: Just on the split of generic and custom that was shared, so when I just add the generic piece and the nutraceuticals together and look at growth on Y-o-Y basis, it seems to be still subdued, like low single digit, like flattish kind of a Y-o-Y trend, even if I look at it compared to the quarter before also, it seems to have declined. So, just want to understand and also reflect upon our guidance for fiscal 24 when we exclude Molnupiravir we are looking at double digit growth, so if you can help us understand that, sir?",
            "|Cyndrella Carvalho|Dr. Murali K. Divi|\n|---|---|\n|And sir, if I may understand that from a 3-4 year perspective, what should be our goal from a topline and the margin perspective, you mentioned 35% to 40% is the larger range, but again the earlier call also, you have mentioned the double digit, should we affirm these two numbers again?|Barring COVID and any unforeseen incidences or issues of China or any other country, we should be able to see good growth, a double digit growth. I don't want to talk too much, but first we need to prove that yes, we are on that track and I think a quarter result towards the Rs. 2,000 crores plus, I think that is what will give confidence again coming out of the Molnupiravir (no sales now), coming out of Rs. 1,700 crores of sales, going towards the Rs. 2,000 crores per quarter, then jumping into the Rs. 2,200 crores per quarter. Ours is, we don't jump, slow, steady, consistent, and debt free, these are our models.|",
            "Dr. Murali K. Divi: I wouldn't say there is a decline in the quantity of generic API, yes, I agree with you the growth of the matured generics is in the single digit, yes, but when you say that in a compound of 5000 tons even a single digit can be substantial, let\u2019s say 5% growth. We are talking about 250 ton growth year-on-year, then there will be always new entrants to take some of the capacity or some of the products from the market, but we are in the advanced markets where it is highly regulated. So there, after the COVID which is over towards the end of the last year, now everything is getting stabilized to see first anti-infective, then antibiotics ant-infectives, then life-saving medicines, lifestyle medicines. We are more into the lifestyle medicines in the generic market. So, now we will see they are stabilized, we will see an improvement and we are the major player there.",
            "Dr. Murali K. Divi: Barring COVID and any unforeseen incidences or issues of China or any other country, we should be able to see good growth, a double digit growth. I don't want to talk too much, but first we need to prove that yes, we are on that track and I think a quarter result towards the Rs. 2,000 crores plus, I think that is what will give confidence again coming out of the Molnupiravir (no sales now), coming out of Rs. 1,700 crores of sales, going towards the Rs. 2,000 crores per quarter, then jumping into the Rs. 2,200 crores per quarter. Ours is, we don't jump, slow, steady, consistent, and debt free, these are our models.\n\nCyndrella Carvalho: And sir, on the Kakinada you have highlighted in the annual report around Rs. 700 crore CAPEX in this FY25 and we are looking at commercialization somewhere second-half of FY25 with the intermediates and the advance material, is it the correct timeline to look forward to?"
        ],
        "ground_truth":"I wouldn't say there is a decline in the quantity of generic API, yes, I agree with you the growth of the matured generics is in the single digit, yes, but when you say that in a compound of 5000 tons even a single digit can be substantial, let\u2019s say 5% growth. We are talking about 250 ton growth year-on-year, then there will be always new entrants to take some of the capacity or some of the products from the market, but we are in the advanced markets where it is highly regulated. So there, after the COVID which is over towards the end of the last year, now everything is getting stabilized to see first anti-infective, then antibiotics ant-infectives, then life-saving medicines, lifestyle medicines. We are more into the lifestyle medicines in the generic market. So, now we will see they are stabilized, we will see an improvement and we are the major player there.",
        "file_name":"Divi's Laboratories.pdf"
    },
    {
        "question":"What portion of this elevated inventory is relating to the high cost base, so that your process of blending with the low cost ones and managing your margin, so that process will continue?",
        "answer":"Most of the high cost procured material has been consumed, which has been reflected in the earlier quarters.",
        "contexts":[
            "|Surya Patra:|But is it possible to kind of indicate, what portion of this elevated inventory is relating to the high cost base, so that your process of blending with the low cost ones and managing your margin, so that process will continue?|\n|---|---|\n|Nilima Prasad Divi:|Well, as I mentioned earlier, most of the high cost procured material has been consumed, which has been reflected in the earlier quarters.|\n|Surya Patra:|And is it fair to understand that the elevated work in progress inventory that is to do with the kind of inventory rationalization that is going on industry wide largely for the APIs, is that the case?|\n|Nilima Prasad Divi:|I wouldn't generalize it as for the entire industry because each organization has their own strategy and way of taking these kind of decisions.|",
            "Moderator: Thank you. The next question is from the line of Surya Patra from PhillipCapital. Please go ahead.\n\nSurya Patra: Sir, my first question is on the inventory provision that we are having, so earlier that we have indicated one of the key reasons for suppressed margins is the high cost inventory what we have been carrying. So, from the annual report, if I see they both are in front of the raw material inventory as well as the work in progress inventory, both have gone up by Rs. 500 crores kind of levels from the normalized level, so when do you think that this high cost inventory or what portion of this is a high cost inventory and when do you think that it would be liquidated, so that you can go back to your normalized margins?",
            "Moderator: Thank you. The next question is from the line of Cyndrella Carvalho from JM Financial. Please go ahead.\n\nCyndrella Carvalho: Congratulations on the guided gross margin improvement, we are seeing this improvement coming and Nilima highlighted that this is driven by lower raw material cost as well as the further improvement in the other expenses that we are seeing is largely the logistical cost also coming down. So, how should we see this, the gross margin. A) is: do we see some improvement in our generic pricing portfolio also or it is purely by the raw material and the B) part is: on the other expenses side, should we see further scope of improvement as we go ahead?",
            "Dr. Murali K. Divi: Yes, not only there is some improvement in the raw material prices, but also there is an improvement happening in the coming quarters by process improvement or by yield improvement and reducing manufacturing costs by energy efficient operations. Because we have to look from the holistic point of view, it is not just raw material prices came down from China or elsewhere, but as a holistic, as Nilima mentioned about the freight outward, carriage outwards coming down from Rs. 2,000 a container, it went up (earlier) to Rs. 12,000 a container and came back to Rs. 2,000 a container by sea. I think these are kind of things, sometimes they go up and come down, but the raw material prices coming down, the process efficiency going up, increasing yields, they will help the Company to be on elephant footing making consistent margins."
        ],
        "ground_truth":"most of the high cost procured material has been consumed, which has been reflected in the earlier quarters.",
        "file_name":"Divi's Laboratories.pdf"
    },
    {
        "question":"Is it fair to understand that the elevated work in progress inventory that is to do with the kind of inventory rationalization that is going on industry wide largely for the APIs, is that the case?",
        "answer":"It is not fair to generalize that the elevated work in progress inventory is solely due to industry-wide inventory rationalization for APIs, as each organization has its own strategy and approach to making such decisions.",
        "contexts":[
            "|Surya Patra:|But is it possible to kind of indicate, what portion of this elevated inventory is relating to the high cost base, so that your process of blending with the low cost ones and managing your margin, so that process will continue?|\n|---|---|\n|Nilima Prasad Divi:|Well, as I mentioned earlier, most of the high cost procured material has been consumed, which has been reflected in the earlier quarters.|\n|Surya Patra:|And is it fair to understand that the elevated work in progress inventory that is to do with the kind of inventory rationalization that is going on industry wide largely for the APIs, is that the case?|\n|Nilima Prasad Divi:|I wouldn't generalize it as for the entire industry because each organization has their own strategy and way of taking these kind of decisions.|",
            "Moderator: Thank you. The next question is from the line of Surya Patra from PhillipCapital. Please go ahead.\n\nSurya Patra: Sir, my first question is on the inventory provision that we are having, so earlier that we have indicated one of the key reasons for suppressed margins is the high cost inventory what we have been carrying. So, from the annual report, if I see they both are in front of the raw material inventory as well as the work in progress inventory, both have gone up by Rs. 500 crores kind of levels from the normalized level, so when do you think that this high cost inventory or what portion of this is a high cost inventory and when do you think that it would be liquidated, so that you can go back to your normalized margins?",
            "Surya Patra: And regards to the question, sir, whether the inventory rationalization happening even for custom synthesis, can you respond, please?\n\nDr. Murali K. Divi: In custom synthesis, there is nothing like inventory as and when they are made, if the first shipment lot is 1 metric ton, (or) if the shipment lot is 5 metric ton as and when the lot is ready, it will go out.\n\nSurya Patra: Sir, just last question, sir, from the carotenoid side, so what is the pricing trend, sir that is one, and secondly, what we have been seeing since last few quarters that it is kind of a stagnated at that level, it is very narrow range. So, are we operating currently at 100% utilization and unless until we see expanded facility, we may not see growth in the carotenoid that is one question? And secondly whether the prices of carotenoid have also seen some impact because of the current situation?",
            "|Dr. Murali K. Divi:|The difference between the API industry and the pharma industry that are in the formulations is different, where for us is the processing industry, so when we buy raw materials at high price, they become the API and gets sold out. Our inventory of API is not high, it is marginal, whereas in the dosage forms, they convert and warehouse them in India, abroad and in the stores. So there is a long gestation period between manufacturing of the dosage form and realizing the sales. That is the reason till that time it will be inventory whereas for us, once you convert to API and out, our inventory is over. The reason it was more 1 year ago, 2 years ago is that for assurance of supply, we procured extra quantities at higher price, anticipating there could be a substantial shortage because of the explosions that happened in China or because of shortages we have seen; that is the reason and the COVID where there were problems of the transportation of these raw materials. That is the reason we have"
        ],
        "ground_truth":"I wouldn't generalize it as for the entire industry because each organization has their own strategy and way of taking these kind of decisions.",
        "file_name":"Divi's Laboratories.pdf"
    },
    {
        "question":"Whether the prices of carotenoid have also seen some impact because of the current situation?",
        "answer":"The prices of carotenoids have not seen any impact due to the current situation.",
        "contexts":[
            "Dr. Murali K. Divi: We have not seen any price pressures in the carotenoids. In fact, our plant of carotenoids is running in the 90-95% capacity. In fact, we needed more capacity of the API of carotenoids that is where, at Unit-3, we are putting additional capacity of carotenoids which will come in line sometime in the Q1-Q2 of next year.\n\nSurya Patra: So, carotenoid is not witnessing any kind of pricing pressure and you are operating at a kind of optimal utilization anyway, so with the input price correction, this is one segment which has seen the best improvement in terms of margin and spreads?\n\nPage 10 of 17\n---\n# Divi\u2019s Laboratories Limited\n\nAugust 14, 2023",
            "Surya Patra: And regards to the question, sir, whether the inventory rationalization happening even for custom synthesis, can you respond, please?\n\nDr. Murali K. Divi: In custom synthesis, there is nothing like inventory as and when they are made, if the first shipment lot is 1 metric ton, (or) if the shipment lot is 5 metric ton as and when the lot is ready, it will go out.\n\nSurya Patra: Sir, just last question, sir, from the carotenoid side, so what is the pricing trend, sir that is one, and secondly, what we have been seeing since last few quarters that it is kind of a stagnated at that level, it is very narrow range. So, are we operating currently at 100% utilization and unless until we see expanded facility, we may not see growth in the carotenoid that is one question? And secondly whether the prices of carotenoid have also seen some impact because of the current situation?",
            "|Surya Patra:|Sir, second question is about the import price correction, so in the general trend, what we are witnessing for the chemical industry, hence for the solvents and all that, there is a dumping from China that is also happening worldwide and that has brought down the prices meaningfully and hence helping API sales more. So, possibly we would have also seen some benefit out of that, but how sustainable or to how long that trend can continue that is one? And secondly, when we are seeing the trend of inventory|",
            "Page 10 of 17\n---\n# Divi\u2019s Laboratories Limited\n\nAugust 14, 2023\n\nDr. Murali K. Divi: Now the import prices coming down need not be carotenoid raw materials because most of the carotenoid raw materials we make it ourselves, we start from the basic materials like ethylene, propylene, ethylene, including\u2026. now we are putting a plant of ethylene production itself. So there we are very strong with base materials. That is not an impact based on the imported raw material. Now, as I mentioned that we are installing additional capacities in Unit-3, it indicates that the demand is much more than right now what we can do. I am not saying there are no competitors, I think we have enough business to expand and needed more capacity.\n\nModerator: Thank you. The next question is from the line of Anirudh Shetty from Solidarity Investment. Please go ahead."
        ],
        "ground_truth":"We have not seen any price pressures in the carotenoids. In fact, our plant of carotenoids is running in the 90-95% capacity. In fact, we needed more capacity of the API of carotenoids that is where, at Unit-3, we are putting additional capacity of carotenoids which will come in line sometime in the Q1-Q2 of next year.",
        "file_name":"Divi's Laboratories.pdf"
    },
    {
        "question":"Carotenoid is not witnessing any kind of pricing pressure and you are operating at a kind of optimal utilization anyway, so with the input price correction, this is one segment which has seen the best improvement in terms of margin and spreads?",
        "answer":"Yes, carotenoid is not experiencing pricing pressure and the company is operating at high capacity utilization. The improvement in raw material prices, process efficiency, yield enhancement, and cost reduction measures are contributing to margin enhancement in the carotenoid segment.",
        "contexts":[
            "Dr. Murali K. Divi: We have not seen any price pressures in the carotenoids. In fact, our plant of carotenoids is running in the 90-95% capacity. In fact, we needed more capacity of the API of carotenoids that is where, at Unit-3, we are putting additional capacity of carotenoids which will come in line sometime in the Q1-Q2 of next year.\n\nSurya Patra: So, carotenoid is not witnessing any kind of pricing pressure and you are operating at a kind of optimal utilization anyway, so with the input price correction, this is one segment which has seen the best improvement in terms of margin and spreads?\n\nPage 10 of 17\n---\n# Divi\u2019s Laboratories Limited\n\nAugust 14, 2023",
            "Surya Patra: And regards to the question, sir, whether the inventory rationalization happening even for custom synthesis, can you respond, please?\n\nDr. Murali K. Divi: In custom synthesis, there is nothing like inventory as and when they are made, if the first shipment lot is 1 metric ton, (or) if the shipment lot is 5 metric ton as and when the lot is ready, it will go out.\n\nSurya Patra: Sir, just last question, sir, from the carotenoid side, so what is the pricing trend, sir that is one, and secondly, what we have been seeing since last few quarters that it is kind of a stagnated at that level, it is very narrow range. So, are we operating currently at 100% utilization and unless until we see expanded facility, we may not see growth in the carotenoid that is one question? And secondly whether the prices of carotenoid have also seen some impact because of the current situation?",
            "Dr. Murali K. Divi: Yes, not only there is some improvement in the raw material prices, but also there is an improvement happening in the coming quarters by process improvement or by yield improvement and reducing manufacturing costs by energy efficient operations. Because we have to look from the holistic point of view, it is not just raw material prices came down from China or elsewhere, but as a holistic, as Nilima mentioned about the freight outward, carriage outwards coming down from Rs. 2,000 a container, it went up (earlier) to Rs. 12,000 a container and came back to Rs. 2,000 a container by sea. I think these are kind of things, sometimes they go up and come down, but the raw material prices coming down, the process efficiency going up, increasing yields, they will help the Company to be on elephant footing making consistent margins.",
            "Moderator: Thank you. The next question is from the line of Cyndrella Carvalho from JM Financial. Please go ahead.\n\nCyndrella Carvalho: Congratulations on the guided gross margin improvement, we are seeing this improvement coming and Nilima highlighted that this is driven by lower raw material cost as well as the further improvement in the other expenses that we are seeing is largely the logistical cost also coming down. So, how should we see this, the gross margin. A) is: do we see some improvement in our generic pricing portfolio also or it is purely by the raw material and the B) part is: on the other expenses side, should we see further scope of improvement as we go ahead?"
        ],
        "ground_truth":"Now the import prices coming down need not be carotenoid raw materials because most of the carotenoid raw materials we make it ourselves, we start from the basic materials like ethylene, propylene, ethylene, including.... now we are putting a plant of ethylene production itself. So there we are very strong with base materials. That is not an impact based on the imported raw material. Now, as I mentioned that we are installing additional capacities in Unit-3, it indicates that the demand is much more than right now what we can do. I am not saying there are no competitors, I think we have enough business to expand and needed more capacity.",
        "file_name":"Divi's Laboratories.pdf"
    },
    {
        "question":"So my first question is, in FY23 we have a gross block of about Rs. 6,800 crores and I presume this is just Unit-1 and 2, so wanted to get a sense of what is the broad range of peak sales that we can kind of generate with this gross block and range is okay with and we have different products and the asset turns will depend on what product mix we are making, so a broad range is fine?",
        "answer":"The peak sales that can be generated with the gross block of about Rs. 6,800 crores in FY23 would depend on the product mix and asset turns. Considering the information provided, a broad range of peak sales can be achieved based on the steady and consistent growth model of the company, aiming for double-digit growth and increasing quarterly sales figures.",
        "contexts":[
            "Moderator: Thank you. The next question is from the line of Anirudh Shetty from Solidarity Investment. Please go ahead.\n\nAnirudh Shetty: I have two broad questions. So my first question is, in FY23 we have a gross block of about Rs. 6,800 crores and I presume this is just Unit-1 and 2, so wanted to get a sense of what is the broad range of peak sales that we can kind of generate with this gross block and range is okay with and we have different products and the asset turns will depend on what product mix we are making, so a broad range is fine?",
            "|Cyndrella Carvalho|Dr. Murali K. Divi|\n|---|---|\n|And sir, if I may understand that from a 3-4 year perspective, what should be our goal from a topline and the margin perspective, you mentioned 35% to 40% is the larger range, but again the earlier call also, you have mentioned the double digit, should we affirm these two numbers again?|Barring COVID and any unforeseen incidences or issues of China or any other country, we should be able to see good growth, a double digit growth. I don't want to talk too much, but first we need to prove that yes, we are on that track and I think a quarter result towards the Rs. 2,000 crores plus, I think that is what will give confidence again coming out of the Molnupiravir (no sales now), coming out of Rs. 1,700 crores of sales, going towards the Rs. 2,000 crores per quarter, then jumping into the Rs. 2,200 crores per quarter. Ours is, we don't jump, slow, steady, consistent, and debt free, these are our models.|",
            "Dr. Murali K. Divi: Barring COVID and any unforeseen incidences or issues of China or any other country, we should be able to see good growth, a double digit growth. I don't want to talk too much, but first we need to prove that yes, we are on that track and I think a quarter result towards the Rs. 2,000 crores plus, I think that is what will give confidence again coming out of the Molnupiravir (no sales now), coming out of Rs. 1,700 crores of sales, going towards the Rs. 2,000 crores per quarter, then jumping into the Rs. 2,200 crores per quarter. Ours is, we don't jump, slow, steady, consistent, and debt free, these are our models.\n\nCyndrella Carvalho: And sir, on the Kakinada you have highlighted in the annual report around Rs. 700 crore CAPEX in this FY25 and we are looking at commercialization somewhere second-half of FY25 with the intermediates and the advance material, is it the correct timeline to look forward to?",
            "Exports for the quarter is about 86%. Exports to Europe and US is about 67%. Product mix for the generics to custom synthesis is 60% and 40% respectively.\n\nWe have a Forex gain of Rs. 3 crores for the quarter as against a gain of Rs. 56 crores in the corresponding quarter of the previous year. Our constant currency growth for the quarter has been negative at 29%. Our nutraceutical business amounted to Rs. 178 crores for this quarter.\n\nWe have capitalized assets of Rs. 33 crores during the quarter. We have a capital work in progress of Rs. 389 crores as at the end of the quarter, of which Kakinada project accounts for Rs. 130 crores.\n\nAs of 31st March, we have cash on book of Rs. 4,208 crores, receivables of Rs. 1,720 crores, inventories of Rs. 2,967 crores. You would notice from our annual report that dividend payout of Rs. 796 crores is scheduled in the first week of September 2023. Thank you.\n\nM. Satish Choudhury: Thank you, ma\u2019am. With this, we would request the moderator to open the line for Q&A."
        ],
        "ground_truth":"Because we have a peculiar situation of projects of custom synthesis, projects of generic and nutraceutical, so some of them need more equipment which will give less value, like some of our 5000 tons of Naproxen or 3000 tons of Gabapentin, they may need large equipment, but at the same time some of the products we do in custom synthesis need a smaller equipment in volume cubic meter capacity, but that will yield higher production value. So it is difficult for us to say gross block, meter cube reactor capacity and so much of crores of business. I think it is very difficult and also in the last 5-8 years, we have started doing, as much as possible, automation and bringing a lot of instrumentation into the processes to bring safety, environment controls, all these add up into the gross block assets.",
        "file_name":"Divi's Laboratories.pdf"
    },
    {
        "question":"Is the right way to look at asset turn, then by segment wise that given the instrument requirement is more in generics, would it be fair to look at what the asset turns could be for generics and what it could be for custom synthesis and if yes, could you share what the asset turns are by segment?",
        "answer":"It is not feasible to differentiate asset turns by segment in this case because the company does not have separate blocks or buildings dedicated specifically to custom synthesis or generics. The company utilizes multi-purpose plants for custom synthesis, and different products go into different buildings based on the stages of chemistry involved. Therefore, it is not possible to provide asset turn figures for generics versus custom synthesis.",
        "contexts":[
            "Anirudh Shetty: Is the right way to look at asset turn, then by segment wise that given the instrument requirement is more in generics, would it be fair to look at what the asset turns could be for generics and what it could be for custom synthesis and if yes, could you share what the asset turns are by segment?\n\nDr. Murali K. Divi: We cannot differentiate because we don't have blocks built for custom synthesis and buildings built for generics. We have buildings dedicated to type of chemistry like chlorination, hydrogenation, so different products go into different buildings for different stages of chemistry, but a product like Molnupiravir or Raltegravir where we have built production buildings as per the requirement of the customer; that is different,\n\nPage 11 of 17\n---\n# Divi\u2019s Laboratories Limited\n\nAugust 14, 2023\n\nbut usually that is not the case. We use our custom synthesis; we use our multi-purpose plants available for that.",
            "Moderator: Thank you. The next question is from the line of Neha Manpuria from Bank of America. Please go ahead.\n\nNeha Manpuria: Sir, in the opening remarks, you mentioned that custom syntheses had a lot of phase 2, phase 3 projects that are doing very well. When should we see conversion of these products into revenue monetization based on the progress that you are seeing, would you say some of these start contributing in FY25-26, based on your assessment, what is the best guess in terms of conversion date of this pipeline?\n\nDr. Murali K. Divi: I think I would like to say in general based on the strengths we have in sartans, based on the strengths we have in contrast media, we should be able to see a good growth in the coming year. I can't be specific on a product or a customer, and I am talking with reference to the big pharma only, contrast media or the sartans.",
            "Surya Patra: And regards to the question, sir, whether the inventory rationalization happening even for custom synthesis, can you respond, please?\n\nDr. Murali K. Divi: In custom synthesis, there is nothing like inventory as and when they are made, if the first shipment lot is 1 metric ton, (or) if the shipment lot is 5 metric ton as and when the lot is ready, it will go out.\n\nSurya Patra: Sir, just last question, sir, from the carotenoid side, so what is the pricing trend, sir that is one, and secondly, what we have been seeing since last few quarters that it is kind of a stagnated at that level, it is very narrow range. So, are we operating currently at 100% utilization and unless until we see expanded facility, we may not see growth in the carotenoid that is one question? And secondly whether the prices of carotenoid have also seen some impact because of the current situation?",
            "Moderator: Thank you. The next question is from the line of Shyam Srinivasan from Goldman Sachs. Please go ahead.\n\nShyam Srinivasan: Just on the split of generic and custom that was shared, so when I just add the generic piece and the nutraceuticals together and look at growth on Y-o-Y basis, it seems to be still subdued, like low single digit, like flattish kind of a Y-o-Y trend, even if I look at it compared to the quarter before also, it seems to have declined. So, just want to understand and also reflect upon our guidance for fiscal 24 when we exclude Molnupiravir we are looking at double digit growth, so if you can help us understand that, sir?"
        ],
        "ground_truth":"We cannot differentiate because we don't have blocks built for custom synthesis and buildings built for generics. We have buildings dedicated to type of chemistry like chlorination, hydrogenation, so different products go into different buildings for different stages of chemistry, but a product like Molnupiravir or Raltegravir where we have built production buildings as per the requirement of the customer; that is different, but usually that is not the case.",
        "file_name":"Divi's Laboratories.pdf"
    },
    {
        "question":"I see for long periods of time you have been between 35% to 40% and in 2021 and 2022 you broke that and went to 40%-43%, so what is the steady state number that you all think you can achieve?",
        "answer":"The steady state EBITDA margin that Divi\u2019s Laboratories Limited believes they can comfortably achieve is between 35% to 40%.",
        "contexts":[
            "Page 11 of 17\n---\n# Divi\u2019s Laboratories Limited\n\nAugust 14, 2023\n\nbut usually that is not the case. We use our custom synthesis; we use our multi-purpose plants available for that.\n\nAnirudh Shetty: And sir, my final question is, I understand that in the near term there could be some short term benefits to our margin as raw material and other costs fall, but when you think about more long term steady state numbers, what kind of EBITDA margin do you think Divi\u2019s can achieve because when I look at your history, I see for long periods of time you have been between 35% to 40% and in 2021 and 2022 you broke that and went to 40%-43%, so what is the steady state number that you all think you can achieve?\n\nDr. Murali K. Divi: I think we used to be 35%-40% before the COVID and with the COVID up and down and when the COVID drug came, again it went up. So we see a stable probably a steady 30%, 35%-40%, I think that is what we can comfortably say.",
            "|Cyndrella Carvalho|Dr. Murali K. Divi|\n|---|---|\n|And sir, if I may understand that from a 3-4 year perspective, what should be our goal from a topline and the margin perspective, you mentioned 35% to 40% is the larger range, but again the earlier call also, you have mentioned the double digit, should we affirm these two numbers again?|Barring COVID and any unforeseen incidences or issues of China or any other country, we should be able to see good growth, a double digit growth. I don't want to talk too much, but first we need to prove that yes, we are on that track and I think a quarter result towards the Rs. 2,000 crores plus, I think that is what will give confidence again coming out of the Molnupiravir (no sales now), coming out of Rs. 1,700 crores of sales, going towards the Rs. 2,000 crores per quarter, then jumping into the Rs. 2,200 crores per quarter. Ours is, we don't jump, slow, steady, consistent, and debt free, these are our models.|",
            "Page 14 of 17\n---\n# Divi\u2019s Laboratories Limited\n\nAugust 14, 2023\n\nenvironment friendly that will allow us to be the leader, but they will add up 2, 3, 4, 5 each year and we expect a much bigger basket than what we are in now. We are not talking about new products, new generics, we are talking about the generic products where we are already in, where we have a presence and we see that they will grow. People are living longer. As I said we are more into lifestyle medicines than lifesaving medicine\u2026. our generic products, so as people live longer they have to use longtime the lifestyle medicines.\n\nCyndrella Carvalho: And sir, if I may understand that from a 3-4 year perspective, what should be our goal from a topline and the margin perspective, you mentioned 35% to 40% is the larger range, but again the earlier call also, you have mentioned the double digit, should we affirm these two numbers again?",
            "Moderator: Thank you. The next question is from the line of Chirag Dagli from DSP BlackRock. Please go ahead.\n\nChirag Dagli: Sir, if I look at the last 4-5 years, your CAGR in INR terms is about 12% and in US dollar terms is about 8%. When you think of your business, do you think which are the two numbers kind of broadly indicates the core business growth because if I look at your EBITDA growth also, it is inching closer to that US dollar growth rather than the INR terms, so just broadly, how do you think about, which number kind of broadly indicates the core growth?"
        ],
        "ground_truth":"I think we used to be 35%-40% before the COVID and with the COVID up and down and when the COVID drug came, again it went up. So we see a stable probably a steady 30%, 35%-40%, I think that is what we can comfortably say.",
        "file_name":"Divi's Laboratories.pdf"
    },
    {
        "question":"When should we see conversion of these products into revenue monetization based on the progress that you are seeing, would you say some of these start contributing in FY25-26, based on your assessment, what is the best guess in terms of conversion date of this pipeline?",
        "answer":"Based on the information provided, it is suggested that a good growth in revenue could be expected in the coming year, particularly in the areas of sartans and contrast media. The company aims for steady and consistent growth, with a focus on proving their track record first. While specific timelines were not mentioned, the company's approach indicates a gradual progression towards increased revenue, potentially reaching Rs. 2,000 crores per quarter and beyond.",
        "contexts":[
            "Moderator: Thank you. The next question is from the line of Neha Manpuria from Bank of America. Please go ahead.\n\nNeha Manpuria: Sir, in the opening remarks, you mentioned that custom syntheses had a lot of phase 2, phase 3 projects that are doing very well. When should we see conversion of these products into revenue monetization based on the progress that you are seeing, would you say some of these start contributing in FY25-26, based on your assessment, what is the best guess in terms of conversion date of this pipeline?\n\nDr. Murali K. Divi: I think I would like to say in general based on the strengths we have in sartans, based on the strengths we have in contrast media, we should be able to see a good growth in the coming year. I can't be specific on a product or a customer, and I am talking with reference to the big pharma only, contrast media or the sartans.",
            "|And sir, on the Kakinada you have highlighted in the annual report around Rs. 700 crore CAPEX in this FY25 and we are looking at commercialization somewhere second-half of FY25 with the intermediates and the advance material, is it the correct timeline to look forward to?|I don't remember that. We did not project any sales of Rs. 700 crores in Kakinada unit.|",
            "Dr. Murali K. Divi: Barring COVID and any unforeseen incidences or issues of China or any other country, we should be able to see good growth, a double digit growth. I don't want to talk too much, but first we need to prove that yes, we are on that track and I think a quarter result towards the Rs. 2,000 crores plus, I think that is what will give confidence again coming out of the Molnupiravir (no sales now), coming out of Rs. 1,700 crores of sales, going towards the Rs. 2,000 crores per quarter, then jumping into the Rs. 2,200 crores per quarter. Ours is, we don't jump, slow, steady, consistent, and debt free, these are our models.\n\nCyndrella Carvalho: And sir, on the Kakinada you have highlighted in the annual report around Rs. 700 crore CAPEX in this FY25 and we are looking at commercialization somewhere second-half of FY25 with the intermediates and the advance material, is it the correct timeline to look forward to?",
            "|Cyndrella Carvalho|Dr. Murali K. Divi|\n|---|---|\n|And sir, if I may understand that from a 3-4 year perspective, what should be our goal from a topline and the margin perspective, you mentioned 35% to 40% is the larger range, but again the earlier call also, you have mentioned the double digit, should we affirm these two numbers again?|Barring COVID and any unforeseen incidences or issues of China or any other country, we should be able to see good growth, a double digit growth. I don't want to talk too much, but first we need to prove that yes, we are on that track and I think a quarter result towards the Rs. 2,000 crores plus, I think that is what will give confidence again coming out of the Molnupiravir (no sales now), coming out of Rs. 1,700 crores of sales, going towards the Rs. 2,000 crores per quarter, then jumping into the Rs. 2,200 crores per quarter. Ours is, we don't jump, slow, steady, consistent, and debt free, these are our models.|"
        ],
        "ground_truth":"I think I would like to say in general based on the strengths we have in sartans, based on the strengths we have in contrast media, we should be able to see a good growth in the coming year. I can't be specific on a product or a customer, and I am talking with reference to the big pharma only, contrast media or the sartans.",
        "file_name":"Divi's Laboratories.pdf"
    }
]